“…APN circulates abundantly in human bloodstream (1 to 30 μg/mL), but its concentration decreases under pathological conditions, such as obesity, especially visceral fat accumulation (6), and type 2 diabetes (7). We and others previously reported that APN protein, but not gene expression, exists in the aortic endothelium, heart, skeletal muscle, proliferative smooth muscle cells, and renal pericytes through binding to T-cadherin, a unique glycosylphosphatidylinositol (GPI)-anchored cadherin (8)(9)(10)(11). Moreover, APN exhibited its protective effects on atherosclerosis (8), cardiac hypertrophy (9), muscle regeneration (10), and renal tubular injury (11) in a T-cadherin-dependent manner.…”